ATE350383T1 - Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen - Google Patents

Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen

Info

Publication number
ATE350383T1
ATE350383T1 AT03793304T AT03793304T ATE350383T1 AT E350383 T1 ATE350383 T1 AT E350383T1 AT 03793304 T AT03793304 T AT 03793304T AT 03793304 T AT03793304 T AT 03793304T AT E350383 T1 ATE350383 T1 AT E350383T1
Authority
AT
Austria
Prior art keywords
epothilones
analogues
synthesis
intermediate products
formula
Prior art date
Application number
AT03793304T
Other languages
English (en)
Inventor
Samuel J Danishefsky
Alexey Rivkin
Fumihiko Yoshimura
Ortega Ana Esther Gabarda
Young Shin Cho
Ting-Chao Chou
Huajin Dong
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/402,004 external-priority patent/US6921769B2/en
Priority claimed from US10/435,408 external-priority patent/US7649006B2/en
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Application granted granted Critical
Publication of ATE350383T1 publication Critical patent/ATE350383T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D419/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms
    • C07D419/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D419/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT03793304T 2002-08-23 2003-08-22 Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen ATE350383T1 (de)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US40582302P 2002-08-23 2002-08-23
US40858902P 2002-09-06 2002-09-06
US42312902P 2002-11-01 2002-11-01
US45615903P 2003-03-20 2003-03-20
US10/402,004 US6921769B2 (en) 2002-08-23 2003-03-28 Synthesis of epothilones, intermediates thereto and analogues thereof
US10/435,408 US7649006B2 (en) 2002-08-23 2003-05-09 Synthesis of epothilones, intermediates thereto and analogues thereof
US49674103P 2003-08-21 2003-08-21

Publications (1)

Publication Number Publication Date
ATE350383T1 true ATE350383T1 (de) 2007-01-15

Family

ID=31950966

Family Applications (2)

Application Number Title Priority Date Filing Date
AT03793304T ATE350383T1 (de) 2002-08-23 2003-08-22 Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
AT06026750T ATE450534T1 (de) 2002-08-23 2003-08-22 Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT06026750T ATE450534T1 (de) 2002-08-23 2003-08-22 Synthese von epothilonen, zwischenprodukte davon, analoga und ihre verwendung

Country Status (18)

Country Link
US (1) US7875638B2 (de)
EP (3) EP1767535B1 (de)
JP (2) JP4791183B2 (de)
KR (1) KR101173510B1 (de)
CN (2) CN102532120A (de)
AT (2) ATE350383T1 (de)
AU (1) AU2003260002B2 (de)
CA (1) CA2496477C (de)
DE (2) DE60330407D1 (de)
DK (2) DK1767535T3 (de)
ES (2) ES2281692T3 (de)
IL (1) IL167046A (de)
MX (1) MXPA05002113A (de)
NZ (1) NZ538522A (de)
PH (1) PH12012501351A1 (de)
PT (2) PT1767535E (de)
SI (1) SI1767535T1 (de)
WO (1) WO2004018478A2 (de)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7384964B2 (en) * 2002-08-23 2008-06-10 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US7649006B2 (en) 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
AU2003264822A1 (en) * 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
ATE452888T1 (de) * 2002-11-07 2010-01-15 Kosan Biosciences Inc Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
KR20060122819A (ko) * 2003-10-09 2006-11-30 코산 바이오사이언시즈, 인코포레이티드 치료학적 제형
CA2585125C (en) 2004-10-25 2014-04-22 Lee Morgan Salts of isophosphoramide mustard and analogs thereof as anti-tumor agents
US7238816B2 (en) 2005-04-21 2007-07-03 Hoffmann-La Roche Inc. Preparation of epothilone derivatives
EP2118079A1 (de) 2007-02-07 2009-11-18 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Synthetische makrozyklische zusammensetzungen zur behandlung von krebs
KR20150139620A (ko) 2007-04-06 2015-12-11 지오팜 온콜로지 인코포레이티드 이소포스포르아미드 머스타드의 염 및 이의 동족체
WO2008141130A1 (en) * 2007-05-11 2008-11-20 Kosan Biosciences, Inc. Process for the preparation of epothilones
WO2009112077A1 (en) * 2008-03-13 2009-09-17 F. Hoffmann-La Roche Ag Process for the preparation of epothilone precursor compounds
SG183657A1 (en) 2008-07-31 2012-09-27 Ziopharm Oncology Inc Synthesis and formulations of salts of isophosphoramide mustard and analogs thereof
WO2010099213A1 (en) 2009-02-24 2010-09-02 Dekk-Tec, Inc. Complexes of 4-hydroperoxy ifosfamide as anti-tumor agents
WO2010138686A1 (en) 2009-05-29 2010-12-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Mdri-inverse agents
CN101747326B (zh) * 2010-01-12 2012-07-25 山东大学 18元大环内酯类埃博霉素化合物及其应用
AU2011224241B2 (en) 2010-03-10 2014-05-08 Sri International The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
WO2013009475A1 (en) 2011-07-11 2013-01-17 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Photosensitizing antibody-phuorophore conjugates
WO2012033601A1 (en) 2010-08-20 2012-03-15 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Thiosemicarbazones with mdr1 - inverse activity
EP2854855B1 (de) 2012-05-25 2016-04-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Verfahren zur regulierung von mit der cannabinoidrezeptoraktivität assoziierten erkrankungen
EP3054987B1 (de) 2013-10-11 2019-10-09 The United States of America, represented by the Secretary, Department of Health and Human Services Tem-8-antikörper und deren verwendung
CA2954463C (en) 2014-08-08 2023-11-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Photo-controlled removal of targets in vitro and in vivo
AU2016347456B2 (en) 2015-10-27 2018-12-13 F. Hoffmann-La Roche Ag Peptide macrocycles against acinetobacter baumannii
WO2019089755A1 (en) 2017-10-31 2019-05-09 Western Oncolytics Ltd. Platform oncolytic vector for systemic delivery
WO2019099615A1 (en) 2017-11-17 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Use of copeptin to modulate the immune response and hematopoiesis, and stimulate bone growth
JP2021511060A (ja) 2018-01-26 2021-05-06 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 腫瘍治療を改善するための、腫瘍微小環境における代謝モジュレーターの発現
US11505573B2 (en) 2018-03-28 2022-11-22 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
WO2019199751A1 (en) 2018-04-10 2019-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination of near infrared photoimmunotherapy targeting cancer cells and host-immune activation
US11819532B2 (en) 2018-04-23 2023-11-21 Hoffmann-La Roche Inc. Peptide macrocycles against Acinetobacter baumannii
MX2022000174A (es) 2019-07-02 2022-05-20 Us Health Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
US12503695B2 (en) 2020-01-27 2025-12-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services RAB13 and NET1 antisense oligonucleotides to treat metastatic cancer
JP2023552289A (ja) 2020-11-19 2023-12-15 カリヴィル イムノセラピューティクス， インコーポレイテッド 腫瘍微小環境リモデリングによる腫瘍溶解性免疫療法
AU2022213415A1 (en) 2021-01-29 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Near infrared photoimmunotherapy (nir-pit) combination therapy to treat cancer
EP4329786A4 (de) 2021-04-30 2024-12-11 KaliVir Immunotherapeutics, Inc. Onkolytische viren zur modifizierten mhc-expression
CN116710085A (zh) * 2021-12-31 2023-09-05 成都华昊中天药业有限公司 优替德隆脂质体组合物及其制备方法和用途
JP2025525451A (ja) 2022-06-30 2025-08-05 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｃｄ２５特異的抗体およびその使用
WO2025014896A1 (en) 2023-07-07 2025-01-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Humanized 40h3 antibody

Family Cites Families (227)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4605661A (en) * 1984-06-18 1986-08-12 Eli Lilly And Company Aromastase inhibiting α,α-diarylimidazole-4(5)-propionitriles, α,α-diarylimidazole-4(5)-propionamides, and 4(5)-(2,2-diarylethyl)imidazoles
EP0225292A3 (de) 1985-12-06 1988-11-30 Ciba-Geigy Ag Einige N-substituierte Buttersäureamidderivate
DE3811574A1 (de) * 1988-03-31 1989-10-19 Schering Ag N-substituierte imidazole, verfahren zu ihrer herstellung sowie ihre verwendung in arzneimitteln
DE4138042C2 (de) 1991-11-19 1993-10-14 Biotechnolog Forschung Gmbh Epothilone, deren Herstellungsverfahren sowie diese Verbindungen enthaltende Mittel
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US20030203976A1 (en) * 1993-07-19 2003-10-30 William L. Hunter Anti-angiogenic compositions and methods of use
DE69403966T3 (de) * 1993-07-19 2008-04-17 Angiotech Pharmaceuticals, Inc., Vancouver Anti-angiogene mittel und verfahren zu deren verwendung
DE59609305D1 (de) 1995-11-17 2002-07-11 Biotechnolog Forschung Gmbh Epothilon-Derivate und deren Herstellung
DE19607702A1 (de) 1996-02-29 1997-09-04 Biotechnolog Forschung Gmbh Heterozyklische Verbindungen, Herstellungsverfahren und Mittel
PL189698B1 (pl) 1996-03-12 2005-09-30 Pg Txl Co Kompozycja farmaceutyczna zawierająca lek przeciwnowotworowy i jej zastosowania
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
US20040106985A1 (en) 1996-04-26 2004-06-03 Jang G. David Intravascular stent
US5917084A (en) 1996-07-03 1999-06-29 Millennium Pharmaceuticals, Inc. Antifungal agents
DE19636343C1 (de) 1996-08-30 1997-10-23 Schering Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B
DE19645362A1 (de) 1996-10-28 1998-04-30 Ciba Geigy Ag Verfahren zur Herstellung von Epothilon A und B und Derivaten
DE19645361A1 (de) 1996-08-30 1998-04-30 Ciba Geigy Ag Zwischenprodukte innerhalb der Totalsynthese von Epothilon A und B, Teil II
US5969145A (en) 1996-08-30 1999-10-19 Novartis Ag Process for the production of epothilones and intermediate products within the process
DE19638870B4 (de) 1996-09-23 2009-05-14 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysine, Verfahren zu ihrer Gewinnung und sie enthaltende Mittel
ATE267197T1 (de) * 1996-11-18 2004-06-15 Biotechnolog Forschung Gmbh Epothilon d, dessen herstellung und dessen verwendung als cytostatisches mittel bzw. als pflanzenschutzmittel
US6204388B1 (en) 1996-12-03 2001-03-20 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6867305B2 (en) * 1996-12-03 2005-03-15 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
EP1386922B1 (de) 1996-12-03 2012-04-11 Sloan-Kettering Institute For Cancer Research Synthese von Epitholonen, Zwischenprodukte, Analoga und ihre Verwendung
US6380394B1 (en) * 1996-12-13 2002-04-30 The Scripps Research Institute Epothilone analogs
US6660758B1 (en) * 1996-12-13 2003-12-09 The Scripps Research Institute Epothilone analogs
DE19701758A1 (de) 1997-01-20 1998-07-23 Wessjohann Ludgar A Dr Epothilone-Synthesebausteine
EP0975638B1 (de) * 1997-02-25 2002-08-07 Gesellschaft für biotechnologische Forschung mbH (GBF) Seitenkettenmodifizierte epothilone
US20020086812A1 (en) 1997-03-04 2002-07-04 Schweinfest Clifford W. Methods and compositions for diagnosis and treatment of cancer
DE19713970B4 (de) 1997-04-04 2006-08-31 R&D-Biopharmaceuticals Gmbh Epothilone-Synthesebausteine II - Prenylderivate
JP4065573B2 (ja) 1997-04-18 2008-03-26 ベーリンガー・インゲルハイム・インテルナツィオナール・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング 反応媒体として圧縮二酸化炭素中における二官能性または多官能性基質の選択的オレフィンメタセシス
DE19849464A1 (de) 1997-04-30 2000-04-27 Schering Ag Wirkstofffreisetzende Stents, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
US6117659A (en) 1997-04-30 2000-09-12 Kosan Biosciences, Inc. Recombinant narbonolide polyketide synthase
DE19821954A1 (de) 1997-05-15 1998-11-19 Biotechnolog Forschung Gmbh Verfahren zur Herstellung eines Epothilon-Derivats
DE19720312A1 (de) 1997-05-15 1998-11-19 Hoechst Ag Zubereitung mit erhöhter in vivo Verträglichkeit
US20030049841A1 (en) * 1997-06-16 2003-03-13 Short Jay M. High throughput or capillary-based screening for a bioactivity or biomolecule
DE19726627A1 (de) 1997-06-17 1998-12-24 Schering Ag Zwischenprodukte, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Epothilon
US6605599B1 (en) 1997-07-08 2003-08-12 Bristol-Myers Squibb Company Epothilone derivatives
DK1001951T3 (da) 1997-07-16 2002-12-23 Schering Ag Thiazolderivater, fremgangsmåde til fremstilling deraf og anvendelse af disse
DE19749717A1 (de) 1997-10-31 1999-05-06 Schering Ag Neue C1-C6-Bausteine zur Totalsynthese neuer Epothilon-Derivate sowie Verfahren zur Herstellung dieser Bausteine
DE19813821A1 (de) 1998-03-20 1999-09-23 Schering Ag Verfahren zur Herstellung von C1-C6-Bausteinen zur Totalsynthese von Epothilon und Epothilon-Derivaten
DE19735578A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue (C1-C6)-Fragmente, Verfahren zur Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
ES2290993T3 (es) 1997-08-09 2008-02-16 Bayer Schering Pharma Aktiengesellschaft Nuevos derivados de epotilona, proceso para su produccion y su utilizacion farmaceutica.
DE19735575A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue (C13-C15)-Fragmente, Verfahren zur Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
DE19751200A1 (de) 1997-11-13 1999-05-20 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19735574A1 (de) 1997-08-09 1999-02-11 Schering Ag Neue [C1(Carboxa)-C6]-Fragmente, Verfahren zu ihrer Herstellung und ihre Verwendung zur Synthese von Epothilon und Epothilonderivaten
DE19744135C1 (de) 1997-09-29 1999-03-25 Schering Ag Beschichtete medizinische Implantate, Verfahren zu ihrer Herstellung und ihre Verwendung zur Restenoseprophylaxe
US6320045B1 (en) 1997-12-04 2001-11-20 Bristol-Myers Squibb Company Process for the reduction of oxiranyl epothilones to olefinic epothilones
US6365749B1 (en) * 1997-12-04 2002-04-02 Bristol-Myers Squibb Company Process for the preparation of ring-opened epothilone intermediates which are useful for the preparation of epothilone analogs
US6096757A (en) 1998-12-21 2000-08-01 Schering Corporation Method for treating proliferative diseases
US6280999B1 (en) 1998-01-23 2001-08-28 Kosan Bioscience Sorangium polyketide synthases and encoding DNA therefor
US6090601A (en) 1998-01-23 2000-07-18 Kosan Bioscience Sorangium polyketide synthase
US6683100B2 (en) * 1999-01-19 2004-01-27 Novartis Ag Organic compounds
KR20080016756A (ko) 1998-02-05 2008-02-21 노파르티스 아게 유기화합물 함유 조성물
DE19804673A1 (de) * 1998-02-06 1999-08-12 Studiengesellschaft Kohle Mbh Verfahren zur Darstellung makrocyclischer Produkte durch ringschliessende Diin-Metathese
US6194181B1 (en) 1998-02-19 2001-02-27 Novartis Ag Fermentative preparation process for and crystal forms of cytostatics
CA2322157C (en) 1998-02-25 2012-05-29 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
FR2775187B1 (fr) * 1998-02-25 2003-02-21 Novartis Ag Utilisation de l'epothilone b pour la fabrication d'une preparation pharmaceutique antiproliferative et d'une composition comprenant l'epothilone b comme agent antiproliferatif in vivo
US6302838B1 (en) 1998-02-25 2001-10-16 Novartis Ag Cancer treatment with epothilones
US6407103B2 (en) 1998-04-21 2002-06-18 Bristol-Myers Squibb Pharma Company Indeno [1,2-c] pyrazol-4-ones and their uses
US6399638B1 (en) 1998-04-21 2002-06-04 Bristol-Myers Squibb Company 12,13-modified epothilone derivatives
US6498257B1 (en) * 1998-04-21 2002-12-24 Bristol-Myers Squibb Company 2,3-olefinic epothilone derivatives
JPH11322611A (ja) * 1998-05-14 1999-11-24 Sankyo Co Ltd 抗ウイルス剤
GB9810659D0 (en) 1998-05-18 1998-07-15 Ciba Geigy Ag Organic compounds
DE19826988A1 (de) 1998-06-18 1999-12-23 Biotechnolog Forschung Gmbh Epothilon-Nebenkomponenten
US6121029A (en) 1998-06-18 2000-09-19 Novartis Ag Genes for the biosynthesis of epothilones
DE19830060A1 (de) 1998-06-30 2000-02-10 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung, Zwischenprodukte und ihre pharmazeutische Verwendung
DE19923001A1 (de) 1999-05-13 2000-11-16 Schering Ag Epothilon-Derivate, Verfahren zu deren Herstellung, Zwischenprodukte und ihre pharmazeutische Verwendung
WO2000001838A2 (en) * 1998-07-02 2000-01-13 The Board Of Regents Of The Leland Stanford Junior University Methods for making polyketides
US20030199535A1 (en) 1998-07-30 2003-10-23 Claudio Cavazza Method for preventing and/or treating peripheral neuropathies induced by the administration of an anticancer agent
EP1117801B1 (de) * 1998-10-02 2006-11-29 Kosan Biosciences, Inc. Polyketid synthase enzyme und rekombinante dna konstrukte dafür, zur herstellung von mit fk-506 und fk-520 verwandten verbindungen
DE19846493A1 (de) 1998-10-09 2000-04-13 Biotechnolog Forschung Gmbh DNA-Sequenzen für die enzymatische Synthese von Polyketid- oder Heteropolyketidverbindungen
DE19848306A1 (de) 1998-10-14 2000-04-20 Schering Ag Verfahren zur Herstellung von Epothilon B und Derivaten sowie Zwischenprodukte für dieses Verfahren
EP1124969A2 (de) 1998-10-29 2001-08-22 Kosan Biosciences, Inc. Rekombinante oleandolid polyketid synthase
US6303767B1 (en) 1998-11-05 2001-10-16 Kosan Biosciences, Inc. Nucleic acids encoding narbonolide polyketide synthase enzymes from streptomyces narbonensis
US6410301B1 (en) 1998-11-20 2002-06-25 Kosan Biosciences, Inc. Myxococcus host cells for the production of epothilones
CN100381566C (zh) 1998-11-20 2008-04-16 科森生物科学公司 产生环氧噻酮及其衍生物的重组方法和材料
BR9916833A (pt) 1998-12-22 2001-09-25 Novartis Ag Derivados de epotilona e seu uso como agentes antitumor
US6780620B1 (en) 1998-12-23 2004-08-24 Bristol-Myers Squibb Company Microbial transformation method for the preparation of an epothilone
US6419692B1 (en) 1999-02-03 2002-07-16 Scimed Life Systems, Inc. Surface protection method for stents and balloon catheters for drug delivery
US6596875B2 (en) 2000-02-07 2003-07-22 James David White Method for synthesizing epothilones and epothilone analogs
DE19908760A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
EE200100431A (et) 1999-02-18 2002-12-16 Schering Aktiengesellschaft 16-halogenoepotilooni derivaadid, nende valmistamismeetod ja farmatseutiline kasutamine
DE19908765A1 (de) 1999-02-18 2000-08-24 Schering Ag 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
WO2000048606A1 (en) 1999-02-18 2000-08-24 Oxigene, Inc. Compositions and methods for use in targeting vascular destruction
US6406722B1 (en) 1999-02-18 2002-06-18 Robert G. Gallaher Method of treating viral infections and lesions with taxane compounds
DE19908767A1 (de) 1999-02-18 2000-10-19 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19908763A1 (de) 1999-02-18 2000-08-24 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19954230A1 (de) 1999-11-04 2001-11-15 Schering Ag 16-Halogen-Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE19907588A1 (de) 1999-02-22 2000-08-24 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
DE19930111A1 (de) 1999-07-01 2001-01-04 Biotechnolog Forschung Gmbh C-21 Modifizierte Epothilone
EE04852B1 (et) 1999-02-22 2007-06-15 Gesellschaft Fuer Biotechnologische Forschung Mbh C-21 modifitseeritud epotioloonid, nende valmistamise meetod ning kasutamine ja ravimkoostise kasutamine vähkkasvajate või teiste proliferatiivsete haiguste ravimisel
US20020058286A1 (en) 1999-02-24 2002-05-16 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
US6291684B1 (en) 1999-03-29 2001-09-18 Bristol-Myers Squibb Company Process for the preparation of aziridinyl epothilones from oxiranyl epothilones
US6211412B1 (en) 1999-03-29 2001-04-03 The University Of Kansas Synthesis of epothilones
US6603015B2 (en) 1999-03-29 2003-08-05 University Of Kansas Synthesis of epothilones
US6514330B1 (en) 1999-04-06 2003-02-04 Seiko Epson Corporation Ink composition containing copper complex colorant
ES2273688T3 (es) 1999-04-14 2007-05-16 Dana-Farber Cancer Institute, Inc. Procedimiento y composicion para el tratamiento de cancer.
CA2366932C (en) * 1999-04-15 2009-08-25 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
US7125875B2 (en) * 1999-04-15 2006-10-24 Bristol-Myers Squibb Company Cyclic protein tyrosine kinase inhibitors
DE19954228A1 (de) 1999-11-04 2001-09-13 Schering Ag 6-Alkenyl-und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
DE10015836A1 (de) 2000-03-27 2001-10-11 Schering Ag 6-Alkenyl- und 6-Alkinyl-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
JP4707240B2 (ja) * 1999-05-05 2011-06-22 アベンティス・フアーマ・リミテッド 細胞接着調節剤としての尿素
KR100621185B1 (ko) 1999-09-09 2006-09-06 삼성전자주식회사 디디씨 모니터의 동작 기록형 마이크로컴퓨터의 제어방법
US6569867B2 (en) 1999-10-01 2003-05-27 Kosan Biosciences, Inc. Polyketide derivatives
US20020147197A1 (en) 1999-10-08 2002-10-10 Newman Michael J. Methods and compositions for enhancing pharmaceutical treatments
US20030054977A1 (en) * 1999-10-12 2003-03-20 Cell Therapeutics, Inc. Manufacture of polyglutamate-therapeutic agent conjugates
US20020045220A1 (en) * 1999-10-13 2002-04-18 Chaitan Khosla Biosynthesis of polyketide synthase substrates
CN1086389C (zh) * 1999-11-12 2002-06-19 中国科学院上海有机化学研究所 异埃坡霉素及合成方法
US20030036177A1 (en) * 2002-08-13 2003-02-20 Joachim Strohhacker Single colonies of myxobacteria cells
WO2001064650A2 (en) 2000-03-01 2001-09-07 Sloan-Kettering Institute For Cancer Research Center Synthesis of epothilones, intermediates thereto and analogues thereof
US6518421B1 (en) * 2000-03-20 2003-02-11 Bristol-Myers Squibb Company Process for the preparation of epothilone analogs
US6593115B2 (en) * 2000-03-24 2003-07-15 Bristol-Myers Squibb Co. Preparation of epothilone intermediates
TWI310684B (en) * 2000-03-27 2009-06-11 Bristol Myers Squibb Co Synergistic pharmaceutical kits for treating cancer
DE10020517A1 (de) * 2000-04-19 2001-10-25 Schering Ag Neue Epothilon-Derivate, Verfahren zu deren Herstellung und ihre pharmazeutische Verwendung
DE10020899A1 (de) 2000-04-20 2001-10-25 Schering Ag 9-Oxa-Epothilon-Derivate, Verfahren zu deren Herstellung sowie ihre Verwendung in pharmazeutischen Präparaten
US6489314B1 (en) 2001-04-03 2002-12-03 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
US6589968B2 (en) 2001-02-13 2003-07-08 Kosan Biosciences, Inc. Epothilone compounds and methods for making and using the same
US6998256B2 (en) * 2000-04-28 2006-02-14 Kosan Biosciences, Inc. Methods of obtaining epothilone D using crystallization and /or by the culture of cells in the presence of methyl oleate
JP2005529579A (ja) * 2000-05-02 2005-10-06 コーサン バイオサイエンシーズ， インコーポレイテッド ポリケチドの生合成のための過剰産生宿主
US20020045609A1 (en) * 2000-05-26 2002-04-18 Gary Ashley Epothilone derivatives and methods for making and using the same
AU7902501A (en) 2000-07-25 2002-02-05 Kosan Biosciences Inc Fermentation process for epothilones
JP2004520008A (ja) 2000-08-09 2004-07-08 コーサン バイオサイエンシーズ， インコーポレイテッド ポリケチドの化学合成において使用するための生物中間体
UA75365C2 (en) * 2000-08-16 2006-04-17 Bristol Myers Squibb Co Epothilone analog polymorph modifications, a method for obtaining thereof (variants), a pharmaceutical composition based thereon
CA2418479C (en) * 2000-08-18 2007-12-18 The Board Of Trustees Of The University Of Illinois Prodrugs of betulinic acid derivatives for the treatment of cancer
US7766956B2 (en) 2000-09-22 2010-08-03 Boston Scientific Scimed, Inc. Intravascular stent and assembly
US6989450B2 (en) * 2000-10-13 2006-01-24 The University Of Mississippi Synthesis of epothilones and related analogs
DE10051136A1 (de) 2000-10-16 2002-04-18 Ludger A Wessjohann Epothilone-Synthesebausteine III und Verfahren zur Herstellung von Epothilon B, D und Epothilonderivaten
AU2002221693A1 (en) * 2000-10-16 2002-04-29 Morphochem Ag Epothilone synthesis components iii and iv: asymmetrically substituted acyloins and acyloin derivatives, method for the production thereof and method for the production of epithilone b, d and epothilone derivatives
US20020169135A1 (en) 2000-11-07 2002-11-14 Pardee Arthur B. Method of treating hematologic tumors and cancers
US7070797B2 (en) * 2000-11-07 2006-07-04 Dana Farber Cancer Institute, Inc. Method of treating hematologic tumors and cancers
WO2002042432A2 (en) * 2000-11-22 2002-05-30 Novartis Ag Epothilone resistant cell lines
GB0029895D0 (en) * 2000-12-07 2001-01-24 Novartis Ag Organic compounds
NZ526871A (en) 2001-01-25 2006-01-27 Bristol Myers Squibb Co Pharmaceutical dosage forms of epothilones for oral administration
DE60225666T2 (de) 2001-01-25 2009-04-16 Bristol-Myers Squibb Co. Verfahren zur herstellung von pharmazeutischen zusammensetzungen enthaltend epothilon-analoga zur krebsbehandlung
SK8552003A3 (en) 2001-01-25 2004-06-08 Bristol Myers Squibb Co Parenteral formulation containing epothilone analogs
US20030004338A1 (en) * 2001-02-01 2003-01-02 Li Wen Sen Process for the preparation of epothilone analogs
US6893859B2 (en) * 2001-02-13 2005-05-17 Kosan Biosciences, Inc. Epothilone derivatives and methods for making and using the same
IL156988A0 (en) * 2001-02-20 2004-02-08 Bristol Myers Squibb Co Pharmaceutical compositions containing epothilone derivatives
EE200300397A (et) * 2001-02-20 2003-12-15 Bristol-Myers Squibb Company Epotilooni derivaadid refraktaarsete kasvajate raviks
ATE335746T1 (de) * 2001-02-27 2006-09-15 Biotechnolog Forschung Gmbh Verfahren zur herstellung von epothilonen
PL207197B1 (pl) 2001-02-27 2010-11-30 Novartis Ag Połączenie obejmujące inhibitor przekazywania sygnału i pochodną epotylonową, kompozycja farmaceutyczna zawierająca to połączenie oraz zastosowanie połączenia
ATE554756T1 (de) * 2001-03-14 2012-05-15 Bristol Myers Squibb Co Kombination aus epothilon-analog und chemotherapeutika zur behandlung von proliferativen erkrankungen
EP1372650B1 (de) 2001-03-19 2008-11-19 Novartis AG Kombinationen, ein antidiarrhoikum und epothilon oder ein epothilonderivat enthaltend
US20020169125A1 (en) 2001-03-21 2002-11-14 Cell Therapeutics, Inc. Recombinant production of polyanionic polymers and uses thereof
WO2002076448A1 (en) 2001-03-23 2002-10-03 Napro Biotherapeutics, Inc. Molecular conjugates for use in treatment of cancer
US7081454B2 (en) * 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
US6900214B2 (en) 2001-03-29 2005-05-31 Bristol-Myers Squibb Company Cyano-substituted dihydropyrimidine compounds and their use to treat diseases
CA2444483A1 (en) 2001-04-26 2002-11-07 Board Of Regents, The University Of Texas System Diagnostic imaging compositions, their methods of synthesis and use
US6906188B2 (en) * 2001-04-30 2005-06-14 State Of Oregon Acting By And Through The State Board Of Higher Education On Behalf Of Oregon State University Method for synthesizing epothilones and epothilone analogs
US20030023082A1 (en) * 2001-05-15 2003-01-30 Gary Ashley Epothilone derivatives and methods for making and using the same
US6800653B2 (en) 2001-06-01 2004-10-05 Bristol-Myers Squibb Compnay Epothilone derivatives
CN1543356B (zh) 2001-06-25 2011-09-28 味之素株式会社 抗肿瘤剂
DE10138347A1 (de) 2001-08-03 2003-02-27 Schering Ag Geschützte 3,5-Dihydroxy-2,2-dimethyl-valeronitrile für die Synthese von Epothilonen- und Derivaten und Verfahren zur Herstellung
US6933385B2 (en) 2001-08-03 2005-08-23 Schering Ag Protected 3,5-dihydroxy-2,2-dimethyl-valeroamides for the synthesis of epothilones and derivatives and process for the production and the use
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
ES2315399T3 (es) * 2001-08-23 2009-04-01 Novartis Ag Analogos de epotilona ciclobutilo y ciclopropilo.
EP1429764A1 (de) 2001-08-31 2004-06-23 Bristol-Myers Squibb Company Zusammensetzungen und verfahren für die krebsbehandlung
US20030176368A1 (en) 2001-09-06 2003-09-18 Danishefsky Samuel J. Synthesis of epothilones, intermediates thereto and analogues thereof
MY141661A (en) 2001-09-06 2010-05-31 Schering Corp 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases
WO2003029195A1 (en) 2001-09-28 2003-04-10 Sumika Fine Chemicals Co., Ltd. Intermediates for epothilone derivative and process for producing these
TW200300350A (en) 2001-11-14 2003-06-01 Bristol Myers Squibb Co C-5 modified indazolylpyrrolotriazines
US20030134883A1 (en) 2001-11-26 2003-07-17 David Myles 14-Methyl-epothilones
EP1453513A1 (de) * 2001-12-03 2004-09-08 Schering Corporation Verwendung von fpt inhibitoren und mindestens zwei anderen ant-krebsmitteln zur krebsbehandlung
DE10164592A1 (de) 2001-12-21 2003-07-03 Schering Ag C1-C6-Epothilon-Fragmente und Verfahren für die Herstellung von C1-C6-Fragmenten von Epothilonen und deren Derivaten
US6884608B2 (en) 2001-12-26 2005-04-26 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
TW200303202A (en) 2002-02-15 2003-09-01 Bristol Myers Squibb Co Method of preparation of 21-amino epothilone derivatives
US6900331B2 (en) 2002-03-01 2005-05-31 University Of Notre Dame Derivatives of epothilone B and D and synthesis thereof
EP1340498A1 (de) 2002-03-01 2003-09-03 Schering Aktiengesellschaft Verwendung von Epothilonen zur Behandlung von mit proliferativen Prozessen assoziierten Gehirnerkrankungen
EP1483267A2 (de) 2002-03-07 2004-12-08 The Board Of Trustees Of The University Of Illinois Mikrotubule-stabilisatoren
AU2003218110A1 (en) * 2002-03-12 2003-09-29 Bristol-Myers Squibb Company C3-cyano epothilone derivatives
US7211593B2 (en) 2002-03-12 2007-05-01 Bristol-Myers Squibb Co. C12-cyano epothilone derivatives
US6900208B2 (en) * 2002-03-28 2005-05-31 Bristol Myers Squibb Company Pyrrolopyridazine compounds and methods of use thereof for the treatment of proliferative disorders
TW200400191A (en) * 2002-05-15 2004-01-01 Bristol Myers Squibb Co Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives
AU2003296878A1 (en) * 2002-05-20 2004-12-13 Kosan Biosciences, Inc. Methods to administer epothilone d
WO2003105828A1 (en) * 2002-06-14 2003-12-24 Bristol-Myers Squibb Company Combination of epothilone analogs and chemotherapeutic agents for the treatment of proliferative diseases
TW200401638A (en) * 2002-06-20 2004-02-01 Bristol Myers Squibb Co Heterocyclic inhibitors of kinases
DE10232094A1 (de) 2002-07-15 2004-02-05 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) 5-Thiaepothilone und 15-disubstituierte Epothilone
TWI329112B (en) * 2002-07-19 2010-08-21 Bristol Myers Squibb Co Novel inhibitors of kinases
KR20050026033A (ko) 2002-07-31 2005-03-14 쉐링 악티엔게젤샤프트 신규 효과기 접합체, 그의 제조 방법 및 그의 약학적 용도
AU2003265349A1 (en) * 2002-08-02 2004-02-23 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
ES2297189T3 (es) * 2002-08-02 2008-05-01 Novartis Ag Derivados de epotilona.
AU2003260723A1 (en) 2002-08-17 2004-03-03 The Queens Universlty Of Belfast Use of vinca alkaloyds, taxane, cryptophycine, ephitoline or eleutherobine for treating alzheimer
AU2003265608A1 (en) 2002-08-21 2004-03-11 Kosan Biosciences, Inc. Myxococcus xanthus bacteriophage mx9 transformation and integration system
US20040126379A1 (en) 2002-08-21 2004-07-01 Boehringer Ingelheim International Gmbh Compositions and methods for treating cancer using cytotoxic CD44 antibody immunoconjugates and chemotherapeutic agents
EP1391213A1 (de) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Zusammensetzungen und Verfahren zur Behandlung von Krebs mit einem Maytansinoid-CD44-Antikörper Immunokonjugat und chemotherapeutische Mittel
US7649006B2 (en) * 2002-08-23 2010-01-19 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
US6921769B2 (en) * 2002-08-23 2005-07-26 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto and analogues thereof
ATE350383T1 (de) * 2002-08-23 2007-01-15 Sloan Kettering Inst Cancer Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
CA2495913A1 (en) 2002-08-23 2004-03-04 Medigene Oncology Gmbh Non-vesicular cationic lipid formulations
DE60313872T2 (de) 2002-09-04 2008-01-17 Schering Corp. Pyrazoloä1,5-aüpyrimidine als hemmstoffe cyclin-abhängiger kinasen
US20040043089A1 (en) 2002-09-04 2004-03-04 Rabie A-Bakr M Buguzhi agent and composition and methods of preparing and administering the same
KR20050058507A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
EP1545533A1 (de) 2002-09-04 2005-06-29 Schering Corporation Pyrazolopyrimidine als hemmstoffe cyclin-abhängiger kinasen
KR20050057139A (ko) 2002-09-04 2005-06-16 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리미딘
GB0221312D0 (en) 2002-09-13 2002-10-23 Novartis Ag Organic compounds
EP1546365A4 (de) 2002-09-16 2006-10-11 Freshcert Llc Durch lebensmittel übertragener krankheitserreger sowie vorrichtung und verfahren zum nachweis des verdorbenseins von lebensmitteln
KR20050072090A (ko) 2002-09-19 2005-07-08 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 피라졸로피리딘
WO2004026867A2 (en) * 2002-09-19 2004-04-01 Schering Corporation Imidazopyridines as cyclin dependent kinase inhibitors
DE10244847A1 (de) 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
HRP20050278A2 (en) * 2002-09-23 2005-10-31 Bristol-Myers Squibb Company Methods for the preparation, isolation and purification of epothilone b, and x-ray crystal structures of epothilone b
KR20060010709A (ko) 2002-09-23 2006-02-02 쉐링 코포레이션 사이클린 의존성 키나제 억제제로서의 신규한 이미다조피라진
JP4799864B2 (ja) * 2002-09-23 2011-10-26 シェーリング コーポレイション サイクリン依存性キナーゼインヒビターとしてのイミダゾピラジン
US20040058899A1 (en) * 2002-09-25 2004-03-25 Klimko Peter G. Use of epothilones and analogs in conjunction with ophthalmic surgery
EP1545529A4 (de) 2002-09-30 2010-03-03 Bristol Myers Squibb Co Neue tyrosinkinase-hemmer
TW200501960A (en) * 2002-10-02 2005-01-16 Bristol Myers Squibb Co Synergistic kits and compositions for treating cancer
BR0315169A (pt) 2002-10-09 2005-08-23 Kosan Biosciences Inc Referência cruzada a pedidos de patente relacionados
JP2006504743A (ja) 2002-10-09 2006-02-09 コーザン バイオサイエンシス インコーポレイテッド 治療製剤
AU2003264822A1 (en) 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
ES2279139T3 (es) 2002-10-15 2007-08-16 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Uso de los derivados de epotilona para el tratamiento del hiperparatiroidismo.
JP2006508126A (ja) 2002-11-06 2006-03-09 アザヤ セラピューティクス インコーポレイティッド 薬学的製剤のタンパク質安定化されたリポソーム製剤
ATE452888T1 (de) 2002-11-07 2010-01-15 Kosan Biosciences Inc Trans-9,10-dehydroepothilon c und d, analoga davon und verfahren zu deren herstellung
EP1585751A4 (de) 2002-11-14 2008-08-13 Celmed Oncology Usa Inc Peptiddeformylase-aktivierte prodrugs
US7645782B2 (en) 2002-11-28 2010-01-12 Wolfgang Richter Thia-epothilone derivatives for the treatment of cancer
US8088605B2 (en) 2002-12-04 2012-01-03 Technologies Biolactics Inc. Exopolysaccharides delivery system for active molecules
DE10256982A1 (de) 2002-12-05 2004-06-24 Schering Ag Neue Effektor-Konjugate, Verfahren zu Ihrer Herstellung und Ihre Pharmazeutische Verwendung
JP2006510626A (ja) 2002-12-05 2006-03-30 シエーリング アクチエンゲゼルシャフト 増殖疾患の処理における部位特異的供給のためのエポチロン類似体
AU2003297832A1 (en) 2002-12-09 2004-06-30 Medtronic Vascular Modular stent having polymer bridges at modular unit contact sites
KR20140148502A (ko) 2002-12-09 2014-12-31 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
CA2510610A1 (en) 2002-12-09 2004-06-24 Novartis Ag Microtubule stabilisers for treating stenosis in stents
CA2549463A1 (en) 2002-12-12 2004-07-01 Conforma Therapeutics Corporation Cytotoxins and diagnostic imaging agents comprising hsp90 ligands
TW200420565A (en) 2002-12-13 2004-10-16 Bristol Myers Squibb Co C-6 modified indazolylpyrrolotriazines
CA2508831C (en) 2002-12-13 2012-05-01 Immunomedics, Inc. Immunoconjugates with an intracellularly-cleavable linkage
GB0230024D0 (en) 2002-12-23 2003-01-29 Novartis Ag Organic compounds
EP1581539A4 (de) 2003-01-03 2007-09-19 Bristol Myers Squibb Co Neue tyrosinkinase-hemmer
WO2004078978A1 (en) 2003-02-26 2004-09-16 Bristol-Myers Squibb Company Compositions and methods for hydroxylating epothilones
GB0305928D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0306907D0 (en) 2003-03-26 2003-04-30 Angiogene Pharm Ltd Boireductively-activated prodrugs
JP2006523235A (ja) 2003-03-28 2006-10-12 コーザン バイオサイエンシス インコーポレイテッド 再狭窄を予防するための装置、方法及び組成物

Also Published As

Publication number Publication date
CA2496477A1 (en) 2004-03-04
NZ538522A (en) 2008-03-28
JP2006502246A (ja) 2006-01-19
EP1506203B1 (de) 2007-01-03
DK1767535T3 (da) 2010-04-12
SI1767535T1 (sl) 2010-03-31
MXPA05002113A (es) 2005-06-03
DE60330407D1 (de) 2010-01-14
EP1506203A2 (de) 2005-02-16
JP2011195589A (ja) 2011-10-06
IL167046A (en) 2012-06-28
PH12012501351A1 (en) 2014-10-13
CN102532120A (zh) 2012-07-04
PT1506203E (pt) 2007-04-30
EP2186811A1 (de) 2010-05-19
DE60310916T2 (de) 2007-11-15
ES2281692T3 (es) 2007-10-01
WO2004018478A3 (en) 2004-12-09
US7875638B2 (en) 2011-01-25
CN1759115A (zh) 2006-04-12
DK1506203T3 (da) 2007-05-14
AU2003260002B2 (en) 2010-03-18
DE60310916D1 (de) 2007-02-15
CA2496477C (en) 2012-10-16
JP4791183B2 (ja) 2011-10-12
US20090149516A1 (en) 2009-06-11
AU2003260002A1 (en) 2004-03-11
KR20050083652A (ko) 2005-08-26
ATE450534T1 (de) 2009-12-15
EP1767535B1 (de) 2009-12-02
KR101173510B1 (ko) 2012-08-21
ES2336937T3 (es) 2010-04-19
PT1767535E (pt) 2010-02-24
WO2004018478A2 (en) 2004-03-04
EP1767535A1 (de) 2007-03-28

Similar Documents

Publication Publication Date Title
DE60310916D1 (de) Synthese von epothilonen, zwischenprodukte dafür, analoga und deren verwendungen
WO2003059898A3 (en) Eponemycin and epoxomicin analogs and uses thereof
ATE406893T1 (de) Pharmazeutische zusammensetzung (kit) enthaltend dihydropyridinonverbindungen und eine verbindung mit immunmodulatorischer (oder antiinflammatorischer) wirkung und ihre verwendung
IL159772A0 (en) Taxol enhancer compounds
BRPI0307351B8 (pt) composto, composição farmacêutica, uso de um composto, e, processo para preparar um composto
EA201000643A1 (ru) Замещенное производное этилендиамина для лечения микобактериальных заболеваний и фармацевтическая композиция на его основе
MXPA04004548A (es) Acidos heteroarilalalcanoicos substituidos y su uso como inhibidores de aldosa reductasa.
ATE288443T1 (de) Neue pyrazin-derivate oder salze davon, pharmazeutische zusammensetzungen, die die derivate oder deren salze enthalten und intermediate zu beider herstellung
GEP20084376B (en) Pyridopyrimidinone compounds, method for production thereof and medicaments comprising the same
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
BRPI0417157A (pt) composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
NO20054787D0 (no) Indenderivater som farmasotiske midler
EE200400031A (et) Biokeemiliste ühendite kompositsioon, selle kasutamine maatriks-metalloproteinaaside pärssimiseks ning seda sisaldav ravimpreparaat
DE60301339D1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
WO2003022844A3 (en) Synthesis of epothilones intermediates thereto and analogues thereof
EP1142573A4 (de) Antibakterielle medizinische zusammenstellung
SE0101038D0 (sv) Novel compounds
FI935800A0 (fi) Antidepressiva och mot Parkisons sjukdom verksamma foereningar
GEP20074058B (en) 4-(7-halo-2-quino(xa) linyloxy-phenoxy-propionic acid derivatives as antineoplastic agents
DE69212331D1 (de) Imidazole derivate und diese enthaltende arzneimittel
AR040441A1 (es) Compuesto de tiol, composicion farmaceutica que lo comprende, su uso para la fabricacion de un medicamento, procedimiento para prepararlo y compuesto intermediario de utilidad en dicho procedimiento
BR0308837A (pt) Composto, composição, método e medicamento para o tratamento de infecções bacterianas, psorìase ou artrite em mamìferos, método e medicamento para o tratamento de toxicidade devido a quimioterapia em um paciente, composição farmacêutica, processo para a preparação de um composto e processo para a conversão dos compostos da fórmula (i) em compostos adicionais da fórmula (i)
WO2005084222A3 (en) Synthesis of epothilones, intermediates thereto, analogues and uses thereof
IL163608A (en) Sulfonanilides are conserved in their amino / amino acids and derivatives, their process, their pharmaceutical preparations, and their conjugated antibodies and their use in the preparation of drugs for the treatment of culture disorders
MY139613A (en) Novel piperazinyl-pyrazinone derivatives for the treatment of 5-ht2a receptor-related disorders

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1506203

Country of ref document: EP